Twist Bioscience: Operational Outperformance, NGS Reacceleration, and Discounted Valuation Support Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on TWST stock, giving a Buy rating on January 8.

Matt Larew has given his Buy rating due to a combination of factors that highlight Twist Bioscience’s stronger-than-expected execution and attractive growth profile. He points to preliminary first-quarter revenue that surpassed both Street and internal forecasts, with robust year-over-year and sequential increases across DNA Synthesis, Protein Solutions, and NGS Applications. Adjusting for the temporary impact from the large oncology diagnostics customer transition, he views the underlying growth rate as consistent with the company’s historical 20%-plus trajectory. Larew also underscores management’s commentary that the NGS business should regain momentum as the fiscal year progresses, reinforcing confidence in the company’s medium-term growth prospects.

In addition, Larew notes that Twist chose to preannounce results around the JPM conference, a departure from past practice that he interprets as a positive signal about near-term visibility and confidence. While the company has not updated its 2026 outlook, he believes current performance is aligned with longer-term targets. Importantly, he highlights that the stock trades at a meaningful discount to the broader omics peer group on a forward sales multiple basis, despite Twist’s solid growth profile. Taken together, the operational outperformance, anticipated reacceleration in NGS, and discounted valuation support his Outperform (Buy) recommendation on the shares.

According to TipRanks, Larew is an analyst with an average return of -0.5% and a 52.50% success rate. Larew covers the Healthcare sector, focusing on stocks such as AptarGroup, MaxCyte, and Danaher.

In another report released on January 8, TD Cowen also maintained a Buy rating on the stock with a $43.00 price target.